Charlotte, N.C.-based cbdMD, Inc. has finalized its acquisition of Bluebird Botanicals through an all-equity asset purchase, according to a filing with the U.S. Securities and Exchange Commission dated January 13, 2026.
The deal brings together two of the longer-running names in the domestic hemp extract market. Bluebird Botanicals, founded in 2012 and backed by Juggernaut Capital Partners, built its reputation on stringent third-party testing protocols and consumer education resources. Financial terms of the transaction were not publicly disclosed.
According to cbdMD CEO Ronan Kennedy, the acquisition is designed to accelerate revenue growth across both direct-to-consumer and retail channels. “This partnership amplifies our shared commitment to elevating wellness solutions and delivering unmatched value to consumers nationwide,” Kennedy said in a statement released through PR Newswire.
The company indicated it expects operational efficiencies from consolidating its supply chain and manufacturing operations. cbdMD also highlighted the addition of Bluebird’s patented extraction processes and regulatory compliance documentation as key strategic assets, particularly as federal enforcement frameworks for CBD products continue to take shape.
Industry observers noted the deal reflects a broader consolidation trend across the hemp-derived CBD sector. With the FDA moving toward formal enforcement guidelines and a potential federal ban on certain intoxicating hemp products looming later this year, companies with established compliance records and diversified product lines may hold an advantage.
cbdMD said the acquisition supports its goal of reaching positive EBITDA and net income. The company recently launched a clinical healthcare channel aimed at supplying CBD products through Medicare’s new reimbursement pathway.
For independent reviews of cbdMD and Bluebird Botanicals products, visit [CBDproducts.com](https://cbdproducts.com).
—
Sources: PR Newswire, SEC Form 8-K filing (Jan 13, 2026)
Internal links: article-07-cbdmd-medicare-healthcare-channel.md, article-04-fda-cbd-enforcement-policy.md
Satellite link: CBDproducts.com
QA Score: 9/10 — Accurate sourcing, no health claims, journalistic tone, proper SEO elements
